Herbalife sales increase, president resigns
This article was originally published in The Tan Sheet
Executive Summary
Herbalife's first-quarter net sales increased 19 percent to $604.4 million, the firm announced May 1. The Los Angeles-based firm says the "record performance" was attributable to double-digit growth in several of is top markets, including the U.S. (14.3 percent), Taiwan (14.8 percent), Italy (29.7 percent), China (111.5 percent), Japan (10.4 percent) and Spain (30.2 percent). In April, Spain health authorities cautioned against Herbalife products citing hepatic toxicity (1"The Tan Sheet" April 28, 2008, In Brief). In addition, President and Chief Operating Officer Gregory L. Probert resigned April 30. Herbalife says the board of directors had no choice but to accept the resignation after reviewing misstatements of Probert's academic credentials. Other Herbalife personnel assumed Probert's responsibilities and Des Walsh, senior VP of worldwide sales, was promoted to executive VP...
You may also be interested in...
Spain recommends precaution for Herbalife products
On April 21, Spain's Ministry of Health issued a "recommendation of precaution when consuming products of the Herbalife brand." The alert cites caution due to "suspicious cases" of "hepatic toxicity presumably associated with the consumption of products from Herbalife." No specific product or ingredient was named. Herbalife says April 23 it is in an ongoing discussion with the agency. The Los Angeles-based firm says it has an adverse event reporting procedure to deal with queries it receives. Herbalife sells 48 products in Spain, including facial creams, shampoo and soap...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.